COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION
    1.
    发明公开
    COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION 有权
    法相结合的疾病与细胞增殖的治疗

    公开(公告)号:EP1827441A1

    公开(公告)日:2007-09-05

    申请号:EP05770228.4

    申请日:2005-08-09

    摘要: The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

    COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION
    4.
    发明授权
    COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION 有权
    法相结合的疾病与细胞增殖的治疗

    公开(公告)号:EP1827441B1

    公开(公告)日:2011-06-15

    申请号:EP05770228.4

    申请日:2005-08-09

    摘要: The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.